



PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Form 1449/A/PTO

(use as many sheets as necessary)

Complete if Known

Application Number	10/026,335
Filing Date	December 21, 2001
First Named Inventor	Sivaram Pillarisetti
Group Art Unit	1619 1644
Examiner Name	Not yet assigned
Attorney Docket Number	18631-0121 (45115-264494)

Sheet	1	of	2
-------	---	----	---

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS

[illegible]


**Examiner
Signature**

David A. Scammon

Date
Considered

2/14/05

ONLY SHEET SUBMITTED



Substitute for Form 1449/A/PTO		C m p l e t e If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/026,335
		Filing Date	December 21, 2001
		First Name of Inventor	Sivaram Pillarisetti
		Group Art Unit	1644
		Examiner Name	
Sheet 1 of 2		Attorney Docket Number	18631-0121 (45115-264499)
OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
dy	AA	Brownlee, M., <i>et al.</i> , "Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking", <u>Science</u> , Vol. 232, pp. 1629-1632, (1986)	
	AB	Brownlee, M., <i>et al.</i> , "Nonenzymatic glycosylation and the pathogenesis of diabetic complications", <u>Annals of Internal Medicine</u> , Vol. 101, pp. 527-537, (1984)	
	AC	Cohen, M.P., <i>et al.</i> , "Role of amadori-modified nonenzymatically glycated serum proteins in the pathogenesis of diabetic nephropathy", <u>Journal of the American Society of Nephrology</u> , Vol. 7, No. 2, pp. 183-190	
	AD	Eitner, F., <i>et al.</i> , "Role of interleukin-6 in mediating mesangial cell proliferation and matrix production <i>in vivo</i> ", <u>Kidney International</u> , Vol. 51, pp. 69-78 (1997)	
	AE	Hofmann, M. A., <i>et al.</i> , "RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/Calgranulin polypeptides", <u>Cell</u> , Vol. 97, pp. 889-901 (1999)	
	AF	Horii, Y., <i>et al.</i> , "Role of interleukin-6 in the progression of mesangial proliferative glomerulonephritis", <u>Kidney International</u> , Vol. 43, Suppl. 39, pp. S-71-S-75, (1993)	
	AG	Huber, S.A., <i>et al.</i> , "Interleukin-6 exacerbates early atherosclerosis in mice", <u>Arterioscler. Thromb. Vasc. Biol.</u> , Vol. 19, pp. 2364-2367	
	AH	Kado, S., <i>et al.</i> , "Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus", <u>Acta. Diabetol.</u> , Vol. 36, pp. 67-72, (1999)	
	AI	Lander, H. M., <i>et al.</i> , "Activation of the receptor for advanced glycation end products triggers a p21 ^{ras} -dependent mitogen-activated protein kinase pathway regulated by oxidant stress", <u>The Journal of Biological Chemistry</u> , Vol. 272, No. 28, pp.17810-17814 (1997)	
	AJ	Li, Y.M., <i>et al.</i> , "Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine", <u>Proc. Natl. Acad. Sci.</u> , Vol. 93, pp. 3902-3907 (1996)	
	AK	Morohoshi, M., <i>et al.</i> , "The effect of glucose and advanced glycosylation end products on IL-6 production by human monocytes", <u>Annals of the New York Academy of Sciences</u> , Vol. 748, pp. 562-570 (1995)	
	AL	Park, L., <i>et al.</i> , "Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts", <u>Nature Medicine</u> , Vol. 4, No. 9, pp. 1025-1031 (1998)	
	AM	Piercy, V., <i>et al.</i> , "Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: A study with aminoguanidine in C57/BLKsJ diabetic mice", <u>Metabolism</u> , Vol. 47, No. 12, pp. 1477-1480 (1998)	
	AN	Saitoh A., <i>et al.</i> , "Urinary levels of monocyte chemoattractant protein (MCP)-1 and disease activity in patients with IgA nephropathy", <u>Journal of Clinical Laboratory Analysis</u> , Vol 12, pp. 1-5, (1998)	
	AO	Schmidt, A.M., <i>et al.</i> , "Activation of receptor for advanced glycation end products", <u>Circulation Research</u> , Vol. 84, pp. 489-497 (1999)	
	AP	Schmidt, A.M., <i>et al.</i> , "Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice", <u>Journal of Clinical Investigation</u> , Vol. 96, pp. 1395-1403 (1995)	
	AQ	Souliis, T., <i>et al.</i> , "Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment", <u>Kidney International</u> , Vol. 50, pp. 627-634 (1996)	
✓	AR	Taguchi, A., <i>et al.</i> , "Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases", <u>Nature</u> , Vol. 405, pp. 354-360 (2000)	
Examiner Signature		David A. Saunders	Date Considered 2/14/05

RECEIVED

MAR 27 2002
FBI CENTER 16022800

